Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Ohio State University
•
General Internal Medicine
•
NCI-CCC Thoracic Tumor Board Question
How would you manage grade 3 treatment-emergent diabetes mellitus (HbA1c of 11.1, anti-GAD65) in a patient with ES-SCLC on atezolizumab maintenance?
Related Questions
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
